PROOF IT WORKS –
March 12, 2021 – According to the Centers for Disease Control and Prevention, 130 Americans die every day from an opioid overdose, which highlights the seriousness of the opioid epidemic and how critical it is for patients to receive comprehensive, meaningful care. The Blue Distinction Center for Substance Use Treatment and Recovery program requires designated facilities to deliver coordinated multidisciplinary care to patients and provide timely access to quality medical and psychosocial care in all phases of treatment. Designated facilities must also offer medication-assisted treatment—an approach to treating opioid addiction that includes both medications and evidence-based psychosocial therapies.
“We are extremely excited and grateful that the Blue Cross Blue Shield Association recognizes the importance of adding substance use disorder as the 11th disease category in its Blue Distinction Specialty Care program. This is huge in so many ways—a sign that addiction treatment has come of age within mainstream health care,” said Bob Poznanovich, vice president of business development at Hazelden Betty Ford.
“Regence’s leadership in vetting addiction treatment providers for quality, evidence-based care and promoting to consumers those with the best demonstrated outcomes will smash historical stigmas, incentivize quality, and protect consumers by providing them with in-network options they can trust,” Poznanovich added. “No one will benefit more from the centers-of-excellence strategy that is growing within health care than the millions of Americans who are facing addiction-related challenges at home or in the workplace. We are proud and thankful to be recognized by Regence and to be part of mainstreaming addiction care so that more individuals and families are able to get the help they need.”
